Sernova, AstraZeneca to Collaborate to Evaluate Potential Therapeutic Cell Applications
By Robb M. Stewart
Biotechnology company Sernova said Wednesday it entered a preclinical research collaboration with AstraZeneca to evaluate the use of its Cell Pouch System in combination with AstraZeneca's novel therapeutic cells.
The company said AstraZeneca is exploring the use of the Cell Pouch System as a potential platform for integration with its development of the next wave of cell therapies for various indications.
Under the terms of the collaboration, AstraZeneca would lead and completely fund the development of the cell technologies and preclinical activities in conjunction with Sernova. The discovery work is being funded and conducted at AstraZeneca, Sernova said.
The preclinical research outcomes would determine the feasibility of potential therapeutic applications and subsequent product development activities between the two companies, it said.
Sernova said it has developed a cell therapy approach for the potential treatment of insulin-dependent diabetes, hypothyroidism and hemophilia A.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 03, 2023 07:38 ET (11:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How to Position Your Investment Portfolio Before the 2024 Election
-
Q2 Update: 2024 Outlook for the Stock Market and Economy
-
6 Stocks to Sell and 6 Stocks to Buy Instead
-
Markets Brief: Will the New Inflation Story Hurt Stocks?
-
Magnificent No More? Apple and Tesla Stocks Are Weighing on the Market
-
What’s Happening In the Markets This Week
-
What Hot Inflation and Delayed Rate Cuts Mean for Investors
-
These 4 Charts Show Plunging Expectations for Fed Rate Cuts
-
19 Best Healthcare Companies to Invest In
-
US Bancorp Earnings: Company Lowers 2024 Guidance for Both Net Interest Income and Expense
-
Best Financial-Services Companies to Own
-
A 5-Star Dividend Stock to Buy With a 3.7% Yield
-
PNC Earnings: Expenses Are Well-Managed; Net Interest Income Will Worsen Before Seeing Improvement
-
Bank of America Earnings: Investment Banking and Asset Management Keep Fees Strong, but Charge-Offs Rise
-
Going Into Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
Johnson & Johnson Earnings: Solid Growth to Start the Year, but We Expect That to Slow by Midyear